Recent Developments Keep Gilead Ahead of the Pack in HIV Treatment Market
Gilead’s announcement of positive Phase III results for its investigational single-tablet regimen (STR), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (TAF), caps a series of developments bolstering the company’s position as HIV treatment market leader, according to an analyst with research and consulting firm GlobalData.
Gilead recently declared that its new drug, an update of Stribild in which tenofovir disoproxil fumarate (TDF) is substituted with TAF, displayed non-inferior virologic efficacy, as well as improved renal and bone tolerability, compared with its predecessor in Phase III clinical trials.
Moritz Herrmann, PhD, GlobalData's Analyst covering Infectious Diseases, says that these results indicate that Gilead’s new STR could compete strongly against ViiV’s recently-approved STR, Triumeq.
Herrmann comments: “Triumeq threatens Gilead’s long-standing dominance in the single-tablet, once-daily, anti-HIV market, as it is the first non-Gilead STR, and also the first regimen to show virologic superiority over Gilead’s Atripla.
“With these new Phase III results, Gilead can effectively address safety concerns surrounding the renal and bone tolerability of its TDF-containing STRs. This positive development is particularly significant given the size of this market, in which Atripla generated sales of over $3.6 billion in 2013.”
In addition, FDA has approved stand-alone antiretroviral agents Tybost and Vitekta, two of Stribild’s components, but has prohibited their co-administration.
Herrmann continues: “There are no clinical or pharmacokinetic data on combinations of either drug as a stand-alone treatment, meaning that Gilead will be unable to foster the uptake of Tybost as an individual agent.
“While the FDA approvals of Tybost and Vitekta will open up some new revenue streams to Gilead’s diverse antiretroviral portfolio, the uptake of these drugs will be limited by the current market landscape and regulatory decisions.”
Janssen’s Rezolsta is currently being developed under a licensing agreement with Gilead for Tybost to treat adult HIV-1 patients in combination with other antiretroviral agents. Herrmann concludes that the positive opinion of Europe’s Committee for Medicinal Products for Human Use towards Rezolsta will further strengthen Gilead’s HIV market position.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance